In the context of mergers and acquisitions, we provide evidence to suggest that a firm's deviation from its optimal financial leverage may impede its ability to undertake future expansions. We also find the negative effect of leverage deviation on acquisition probability to be moderated by firms’ existing capabilities. Further, we find those deviating firms to have better prospects of achieving growth when they pursue cross‐industry and/or cross‐country mergers and acquisitions. Overall, our findings imply that deviations from the optimal financial leverage may be costly to firms but this cost is not symmetric across all firms and all deal types.
No takes yet. Share an insight, caveat, or question.
Agyei‐Boapeah et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: